Health inequalities modular update to NICE health technology evaluations: the manual (PMG36) Methods / process manual consultation NICE process and methods 31 January 2025 Highly specialised ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

Tirzepatide's gastrointestinal adverse effects could lead to dehydration and in turn a deterioration in renal function including acute renal failure. Older people and some other groups of people may ...

Following the Technology Appraisal Committee meeting on 13 August 2024, we are consulting with consultees and commentators on the case for extending the statutory 3-month period for funding of ...

Tirzepatide should be thought about as an option for individual people in line with NICE's guideline on overweight and obesity management. The visual summary care pathway has an overview. Table 4 is ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

We have a library of over 200 quality standards and a single menu of indicators. They can be used to help define and measure quality in health, public health and social care. They can be used by ...